While APP/PS1 mice recapitulate key gut microbiota alterations seen in human AD (e.g., elevated F/B ratio, reduced SCFA producers), future clinical studies should validate whether DSS-induced microbial remodeling translates to improved cognition and reduced neuropathology in AD patients. This evidence concerns the gene APP and Alzheimer disease.